Business Monitor International

Czech Republic Medical Devices Report

Published 17 April 2014

  • 159 pages
Czech Republic Medical Devices Report

Espicom Industry View: The Czech medical device market is expected to grow by a CAGR of 5. 5 % over the 2013-2018 period, a longside increase s in GDP and health expenditure . The amount of funding within the health sector may fall, however, due to the new coalition government's decision to abolish certain healthcare fees. The Czech Republic is heavily reliant on imported medical devices , although domestically manufactured products are of an increasingly good quality and remain competitive in terms of price.

Headline Industry Forecasts

  • In 2013, the Czech medical device market was estimated at US$1,308.5mn, or US$124 per capita. This market size was twice that of Ukraine; in per capita terms, the market was similar to Estonia. The 2008-2013 CAGR was estimated at -0.4% but the market is expected to expand at a CAGR of 5.5% over the 2013-2018 period, reaching US$1,711.2mn, or US$160 per capita by 2018.

  • Around 81% of the medical device market is supplied by imports. The Czech Republic imported medical devices valued at US$1,087.7mn in 2012; this represented a decrease of 9.7% compared with 2011 and a 2007-2012 CAGR of 4.7%. Imports grew every year between 2003 and 2011, except for 2010.

  • The Czech Republic exported medical devices worth US$984.2mn in 2012, representing an increase of 2.5% over 2011 and a 2007-2012 CAGR of 8.2%. The trade deficit decreased notably from -US$243.7 in 2011 to -US$103.5mn in 2012, due to falling imports.

  • The Czech Republic has a broad range of medical device manufacturers, although very few are significant in a global context. The increasing presence of foreign manufacturers in the Czech market has forced indigenous manufacturers to improve their quality in order to compete effectively. Domestic medical device production is estimated to be in excess of US$1.2bn.

Headline Industry Risk/Reward Ratings

  • The Czech Republic is the third most attractive market in Central & Eastern Europe (CEE) in which to commercialise a...


The Czech Republic is the second richest country in Central & Eastern Europe in per capita terms, with a figure of US$18,458 in 2013. Total GDP is the third highest in the region, at US$195.5bn. The Czech Republic is currently experiencing a recession which is expected to last throughout much of 2013, but GDP is projected to increase by an average 2.4% per annum between 2014 and 2018, reaching US $266.8bn, or US$24,535 per capita.

Healthcare funding is largely public, and mainly through health insurance. Private spending only accounts for an estimated 18% of total health expenditure. Provision of care is also largely public; the Czech Republic has yet to develop a substantial private sector.

The MoH plans to introduce a new set of health reforms in 2014 that aim to bring the Czech health system up to EU standards and cut costs. The measures include increasing the fee that patients must pay to visit a doctor, raising fees for patients who wish to see a specialist without a GP referral and extending the list of treatments not covered by health insurance.

Around 81% of the medical device market is supplied by imports. In the 12 months to April 2013, Czech imports decreased by 6.0%, to US$1,101.5mn. Decreases were seen in all sectors, particularly dental products (14.6%) and patient aids (11.8%).


Espicom's highly-regarded world medical technology and device market research reports provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the medical equipment market in context. The reports provide:

  • Unique projected estimates of market size and growth for 33 equipment categories
  • Five year statistical data for key economic and healthcare indicators
  • Information on regulation, distribution and market access
  • Detailed Medical trade data
  • Data on leading local/multinational medical equipment players in the market


  • Evaluate the potential of the market
  • Assess risks and opportunities on the basis of knowledge
  • Profile the market for new product, licences or collaborations
  • Understand the operating and regulatory environment
  • Gain a complete picture on health expenditure and infrastructure
  • Review the competitive environment
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%